The company is evaluating an agonistic (immunostimulatory) humanised monoclonal antibody, dubbed CPI-006, which is said to show a potential new approach to immunotherapy of infectious diseases and cancer.
On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of
The trial is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Regeneron has used
Trastuzumab deruxtecan was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Validation confirms that the application is complete and commences the scientific
As part of the conditional marketing authorisation, Veklury will be used to treat Covid-19 disease in adults and adolescents, aged 12 years and older and weighing at least
As part of the agreement, KKR will acquire its stake from the founding Mody family at a purchase price of INR 745 per share and make an open
Rukobia is a novel attachment inhibitor, which is designed to treat HIV-1 infection, is specified for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE)
The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. The manuscript describing the preliminary
As a result of the approval, Janssen is currently collaborating with the World Health Organisation (WHO) on vaccine pre-qualification to advance the registration of its preventive Ebola vaccine
Cirmtuzumab is an investigational anti-ROR1 monoclonal antibody being evaluated in clinical trials in patients with MCL, CLL and HER2-negative breast cancer. Under the Orphan Drug Act, the FDA
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.